Juan J. Pérez Villar, PhD
CEO, holds a MS degree in Biochemistry and a PhD in Immunology and Inflammation from the Autónoma University of Madrid (UAM), developed an extensive international career in the biopharmaceutical industry in drug discovery and business development. Previously, was the business development managing partner at Biolty (Madrid, Spain) a biopharma consultancy; group head of oncology at Agensys / Astellas Inc. (Santa Monica, CA, USA) and Bristol-Myers Squibb Co. (Princeton, NJ, USA). Juan participated in pre-clinical development of biologics such as abatacept/Orencia® and belatacept/Nulojix® both modulators of the CD28 co-stimulatory activity for inflammation and transplantation; the AGS-PSCA mAb in advanced pancreatic cancers and the small molecule dasatinib (Sprycel®), a multiple tyrosine kinase inhibitor for chronic myeloid leukemia; additionally, he is the inventor of numerous granted patents in the USA and Europe and peer reviewed publications. Previously, he participated in fund-raising activities for a venture capital fund and the launching of a cancer therapeutic vaccine company.
Marta Compte Grau, MD, PhD
I+D Director. Marta attended medical school at Navarra University (Pamplona, Spain) and Hospital Universitario Puerta de Hierro where completed her residency in Immunology; soon after, attended the Molecular Medicine Program at the Mayo Clinic (Rochester, MN, USA) where she worked with Richard Vile in the development of novel cancer immunology strategies. Further, she earned a PhD in Immunology from the Autónoma University of Madrid (UAM). Marta has extensive experience in antibody engineering and development of gene and cellular immunotherapeutic strategies against cancer based on recombinant bispecific antibodies.
Additional team members
Dr. Susana Frago Moreno
Holds BScs in Biochemistry and Organic Chemistry and a PhD in Biochemistry and Molecular and Cellular Biology, both from the University of Zaragoza. Her PhD thesis focused on the molecular mechanisms of electron transfer in flavoproteins. She was a visiting scientist at the Emory School of Medicine (Atlanta, USA), UCD Conway Institute of Biomolecular and Biomedical Research (Dublin, Ireland) and the Institute of Plant Biochemistry and Photosynthesis (CSIC, Sevilla,
Spain). In 2009 She moved to Sir William Dunn School of Pathology in the University of Oxford (UK) for her postdoctoral research, where she applied her biophysics and protein background in the development of a ligand trap for therapeutic applications in cancer. At the end of 2016 she joined the Spanish National Centre for Cancer Research (CNIO) and obtained a Marie Skłodowska-Curie Fellowship to study the mechanisms of tumour metastasis in melanoma. Following her interest in oncoimmunology and innovative immunotherapy treatments, she joined the Antibody Engineering Department of LeadArtis in 2022 to work in the development of the new and revolutionary proprietary Trimerbodies.
Dr Rocío Navarro Ortiz
Holds a BSc (Molecular and Cellular Biology), a MSc (Biotechnology) from the Autonoma University (Madrid). Prior to joining Leadartis she was in the Department of Molecular Immunology at Puerta de Hierro Hospital under the supervision of Dr Laura Sanz. During this time, she acquired extensive knowledge and skills in Molecular and Cellular Biology, Immunology and Cancer Therapies. Subsequently, she obtained her PhD in Molecular Biosciences in 2019 from the Autonoma University (Madrid) and focused her interest in tumor immunology, immunotherapeutic strategies and development of antibodies for cancer treatment. Currently, she leads the mRNA Antibody Development Department in Leadartis, a revolutionary technology with a lot of potential in Medicine.